Scaling up treatment for multidrugr esistant tuberculosis is a global health priority. However, current treatment regimens are long and associated with side effects, and default rates are consequently high. This systematic review aimed to identify strategies for reducing treatment default.
B A C K G R O U N D :
Scaling up treatment for multidrugr esistant tuberculosis is a global health priority. However, current treatment regimens are long and associated with side effects, and default rates are consequently high. This systematic review aimed to identify strategies for reducing treatment default.
M E T H O D S :
We conducted a systematic search up to May 2012 to identify studies describing interventions to support patients receiving treatment for multidrugr esistant tuberculosis (MDR-TB). The potential influence of study interventions were explored through subgroup analyses.
R E S U LT S :
A total of 75 studies provided outcomes for 18 294 patients across 31 countries. Default rates ranged from 0.5% to 56%, with a pooled proportion of 14.8% (95%CI 12.4-17.4). Strategies identified to be associated with lower default rates included the engagement of community health workers as directly observed treatment (DOT) providers, the provision of DOT throughout treatment, smaller cohort sizes and the provision of patient education. C O N C L U S I O N : Current interventions to support adherence and retention are poorly described and based on weak evidence. This review was able to identify a number of promising, inexpensive interventions feasible for implementation and scale-up in MDR-TB programmes. The high default rates reported from many programmes underscore the pressing need to further refine and evaluate simple intervention packages to support patients. K E Y W O R D S : default; retention; MDR-TB THE MULTIDRUG-RESISTANT tuberculosis (MDR-TB) pandemic is rising in prevalence and global importance. There were an estimated 650 000 cases of MDR-TB cases worldwide in 2010, with <5% of all TB patients tested for multidrug resistance. 1 Historically, proportions of MDR-TB among TB cases have been highest in Eastern European countries, although in absolute numbers China and India now contribute 50% of all new MDR-TB cases. 2 Furthermore, in sub-Saharan Africa, the human immunodefi ciency virus (HIV) epidemic and limited resources for comprehensive MDR-TB programmes have aided the spread of MDR-TB and the emergence of extensively drugresistant TB (XDR-TB). 3 MDR-TB, defi ned as Mycobacterium tuberculosis resistant to isoniazid and rifampicin, is more costly and complex to treat than fully susceptible disease, with treatment typically lasting at least 18 months. XDR-TB is defi ned as MDR-TB with additional resistance to a fl uoroquinolone and a second-line injectable agent. 2 Current approaches to treating MDR-TB rely on lengthy treatment durations (typically a minimum of 20 months) using drugs associated with substantial toxicities, often resulting in high default rates. Other reported factors infl uencing treatment default include high costs of treatment for patients in settings where patients must pay, 4 indirect costs such as loss of wages, 5 increased poverty and sex discrimination, 6 dissatisfaction with health care worker attitudes, 7 limited knowledge and negative beliefs and attitudes to treatment, 8 challenges with drug procurement and sustained supply of second-line drugs, substance abuse and psychiatric disorders. 9 Defaulting from treatment is of both medical and public health concern, as patients are at higher risk of mortality and morbidity, and may contribute to further spread of MDR-TB in the community. 10, 11 A study in Peru found that half of defaulters had died within 3 years. 12 It is therefore important to identify effective methods to support patients throughout the duration of treatment. Current guidelines propose a range of potential interventions, such as psychosocial and economic support, but these are poorly supported by evidence.
This systematic review and meta-analysis aims to identify programmatic interventions that can i mprove adherence to and reduce default from MDR-TB treatment.
METHODS
This review was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses: guidance for reporting of systematic reviews and meta-analyses). 13 
Search strategy and selection criteria
We carried out the review in three parts. First, an initial selection was made of studies included in two previous systematic reviews of MDR-TB treatment outcomes 14, 15 to identify relevant papers published between 1965 and December 2008 (the search dates for these reviews): 52 papers met the inclusion criteria and were included in the review. Second, to identify papers published after 2008, a new search was conducted to identify studies published between 1 December 2008 and 1 May 2012. Two databases were searched, Medline via OVID and EMBASE, using the highly sensitive search strategy (see Appendix A Table)* including the search terms drug resistance, TB and treatment outcomes both as free word and MeSH terms. No geographic restrictions were applied. Finally, we contacted experts in the fi eld and hand-searched bibliographies of relevant articles. 16, 17 A standardised web survey was developed (see Appendix A Figure) and sent to authors of included studies to gain further information on patient support strategies. All articles were screened by one reviewer (AT) and verifi ed by a second reviewer (NF).
Eligibility criteria
We included studies published in English that reported fi nal outcomes on treatment for cohorts of at least 10 adult culture-confi rmed MDR-TB patients with access to second-line drugs and at least fi rst-line drug susceptibility testing. Studies were excluded if they were conducted exclusively among children, provided only interim outcomes (defi ned as ⩽12 months on treatment) to avoid bias towards a lower default rate, or studies reporting outcomes on fewer than 10 patients. Our outcome of interest was default, as adherence to treatment is far less commonly reported. If studies included outcomes for patients who had not yet completed treatment, these patients were excluded from the analysis. Studies conducted in the same location during the same time period were considered as potential duplicates; this was verifi ed by contacting authors. Default was defi ned as treatment interruption for ⩾2 consecutive months for any reason without medical approval. 2 
Data extraction and analysis
One reviewer (AT) extracted data on default from MDR-TB treatment programmes, and details of interventions used to improve retention in care. Data were entered into an Excel spreadsheet (Microsoft, Redwoods, WA, USA), and verifi ed by a second reviewer (NF). Variables were classifi ed into three broad categories: provision of treatment, counselling and incentives/enablers. Point estimates and 95% confi dence intervals (CIs) for the proportion of people who d efaulted from treatment are described. Raw proportions were stabilised by arcsine square-root transformation, and proportions were then pooled using a DerSimonian-Laird random effects model and the τ 2 statistic calculated as an estimate of betweenstudy variance. 18, 19 Sub-group analyses were carried out to determine the potential infl uence of various interventions, as well as the impact of geographic region (as defi ned by the World Health Organization [WHO] 20 ), economic classifi cation (as defi ned by the World Bank 21 ) and MDR-TB burden (as defi ned by the WHO). 22 
RESULTS
The search strategy identifi ed 974 studies, of which 75 papers reporting outcomes on 78 different programmes were taken through for review (Figure 1) .
Characteristics of studies included
Our review includes data from 18 294 patients; studies reported a range of patient cohort sizes from 13 to 1407 patients. Studies reported over a time period from 1982 to 2011, and took place across 31 countries, with the largest numbers originating from India, South Africa, South Korea, Peru, the United States and Russia (6-10 studies each); 23 studies originated from high-income countries, 32 from upper middleincome countries, 18 from lower middle-income countries and only 2 from low-income countries (Appendix B). Provision of treatment The majority of the studies (58 studies, 13 826 patients) used individualised regimens, 17 (4289 patients) used a standardised regimen and 2 (139 patients) used a mixture of both. Directly observed treatment (DOT) was provided throughout the course of the treatment in 36 studies (7635 patients), 24 (6635 patients) provided partial DOT, and 10 (3352 patients) did not administer treatment under DOT. The DOT provider was a nurse in 21 studies (6012 patients), a community health worker (CHW) in 7 (916 patients), a family member in 2 (38 patients) and a mixture of providers in 17 (2345 patients). Location for DOT was in a facility (hospital or clinic) for 36 studies (9845 patients), at home for 3 (180 patients) and at a mix of facility and home for 20 (3830 patients). The study cohorts varied in size, with 40 studies reporting outcomes on cohorts of fewer than 100 patients, 3 25 reporting outcomes on a cohort of 100-499 patients, 8 reporting outcomes on a cohort of 500-999 patients and 5 reporting outcomes on a cohort of over 1000 patients.
Counselling and education
Counselling was reported to have been provided throughout the course of treatment in 16 studies (2802 patients), through education, psychiatric care, group therapy or psychosocial support. The most common of these was psychosocial support, reported to be available in 13 studies (1989 patients). Patient education, with or without family involvement, was reported in 10 studies (1495 patients), group therapy in 3 (749 patients), provision of psychiatric care in 3 (1274 patients) and substance abuse specialist support was reported in 1 (38 patients).
Incentives/enablers
Incentives or enablers were reported to have been provided in 47 studies (9560 patients), most commonly in the form of nutrition support (28 studies, 5642 patients), followed by transport reimbursement (18 studies, 3662 patients) and accommodation (14 studies, 1915 patients). 
Rates and determinants of treatment default
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We undertook a range of subgroup analyses to identify factors that may infl uence treatment default. The full range of subgroup analyses are reported in Appendix D, and the most important and programmatically relevant of these are summarised in Figure 2 .
There was a lower default rate when DOT was always provided compared to when no DOT was provided, and when the DOT provider was a CHW compared with a health care worker in a facility or nurse. Cohort size was also found to be infl uential, with lower default rates in smaller programmes. The use of a standardised regimen also appeared to result in lower default rates compared to individualised regimens. The provision of counselling did not appear to infl uence default, but provision of patient education did ( Figure 2) .
A broad range of incentives and enablers were assessed, but none were found to obviously reduce default from treatment, alone or in combination. The only potential difference was seen when comparing the delivery of a package of fi nancial support, nutrition and transport reimbursement, which was associated with a lower default rate (9.7%, 95%CI 7.5-11.8), compared to studies that did not provide this combination of interventions (15.1%, 95%CI 12.5-17.7, P = 0.002).
Default rates were not found to be associated with study design, geographic region, economic classification or national drug-resistant TB rates. Finally, fi ve studies used legal action to enforce adherence to treatment. 60, 65, 74, 75, 86 There was no difference between these studies (12.3%, 95%CI 1.5-23.1) and those that did not use legal action (15.1%, 95%CI 12.4-17.8, P = 0.62).
Comparison of the 10 studies with the lowest and highest default rates
To further explore drivers of default, we compared studies with the highest and lowest default rates. Among the studies with low default rates, three provided interim outcomes before the end of treatment: two reported outcomes after 12 months, resulting in default rates of 0.7% (95%CI 0.03-2.30) 62 and 1.27% (95%CI 1.13-10.62), 80 and a third calculated default after 17 months of treatment (proportion defaulting 1.69%, 95%CI 0.70-6.44). 68 However, when these studies were dropped from the overall analysis, the overall default rate remain unchanged (15.7%, Reducing default in drug-resistant TB 5 95%CI 13.0-18.5). In the group of studies with low default rates, a prospective cohort study based in Thailand used a comparative cohort design to assess the use of mobile phone reminders to improve adherence to treatment. 68 Both groups provided DOT at home by a family member throughout the standardised treatment regimen, and medication education provided by a pharmacist. Default rates for both groups were low, at 1.3% (95%CI 1. 13-10.62) . Only fi ve of the 10 countries with the highest default rates are classifi ed as lower middle-income countries, compared to 9/10 countries with the lowest default rates classifi ed as either upper middle-income or high-income counties. Three of the studies from South Korea 52,57,59 with high default rates, and one from India 38 with low default rates, charged the patients for treatment.
Reporting quality
All studies were observational, and the majority were retrospective in design, which carried the risk of bias and confounding of results. The quality of reporting varied considerably. Prior treatment history was poorly reported, with the majority of the studies (n = 60) reporting mixed cohorts with variable proportions of newly treated patients and previously treated patients. While this may bias outcomes, it nevertheless refl ects programmatic reality. Other important variables were inconsistently reported: 8 studies did not state whether or not DOT was administered, 18 studies did not state DOT location and 27 did not report DOT provider.
DISCUSSION
The WHO has established a goal of universal access to diagnosis and treatment of MDR-and XDR-TB by 2015. 22 However, even if this goal is achieved, there is a risk that much of this progress will be undone by high default rates with a concomitant risk of mortality, resistance amplifi cation and ongoing community transmission. This review identifi ed several relatively simple, inexpensive interventions that have the potential to reduce default: engagement of CHWs as DOT providers; provision of DOT throughout treatment; limiting cohort size through, for example, decentralisation of services; providing patient education; and a package of adherence interventions. The benefi cial impact of these interventions reinforces the concept that the provision of treatment closer to the community level, and in a patient-centred manner, contributes to improved retention in care. Another notable fi nding is the association between larger programme size and increased default.
The fi nding that studies providing DOT through CHWs rather than nurses or health care workers in a facility appeared to reduce default may provide a way both to improve adherence and to rationalise health service use, thus freeing up health worker time for clinical tasks. Furthermore, the use of CHWs in a decentralised environment has been found to be affordable, without compromising treatment success rates. 98 The benefi cial effects of DOT are unlikely to be the result of DOT alone, and include motivating and reassuring patients as to their treatment progress and early identifi cation of side effects on a daily basis. 99 Health care workers in busy health care settings are likely to have less time to provide comprehensive patient support and take a narrow interpretation of DOT as simply watching patients take their medication. In addition, CHWs are generally quicker to train than nurses and clinicians, and have been demonstrated to improve adherence to treatment for other infectious diseases, such as HIV. 100 The association between lower default rates and the use of standardised regimens may refl ect a benefi t in terms of simplifying treatment regimens and sideeffect management, and allowing for a more consistent and reliable supply of drugs 101 (in one study, stockouts were a cause of non-adherence to treatment 95 ). It is important to note, however, that treatment outcomes tend to be better for patients on individualised regimens. 15 This highlights the diffi cult trade-off between simplicity and effi cacy using currently available drugs, and suggests there might be a role for a choice of standardised regimens in patient management which could be tailored to an individual's results.
Studies that used a comprehensive package of a dherence interventions (including fi nancial support, transport reimbursement and nutrition) tended to have lower default rates. While such interventions have a cost, they may be less costly than the consequences of default. However, only a few studies reported using such interventions in combination. The use of an outpatient model of care may not only improve convenience to the patient, it has also been found to be more cost-effective than in-patient care, 4 allowing greater investment in patient support and packages of incentives and enablers. There is a need for further research focusing on the cost-effectiveness of interventions to improve patient retention.
The observation that default rates tended to increase with cohort size could be because smaller cohort study settings may be more likely to be able to provide better quality care, as there are a smaller number of patients to manage. Health facility factors may also help explain this association, but we were unable to extract information on staff to patient ratio, quality of staff training and waiting times. Nevertheless, this indicates the potential for decentralised care utilising CHWs as a way of scaling up MDR-TB treatment without increasing default rates.
Legal action to enforce adherence to treatment gave mixed results, but overall did not appear to reduce default or help retain patients in care. Consideration of such approaches must be balanced against the human rights implications, and the potential consequences of discouraging other patients from coming forward for diagnosis and treatment are signifi cant. 102 Finally, the lack of association between default and geographic variation or economic status shows that similar levels of retention in care can be achieved in a range of settings.
Strengths and limitations
The studies included in this review are subject to a number of limitations. Most studies were retrospective, observational studies, which may result in reporting bias and unmeasured confounding. The wide range of study settings, patient populations and interventions resulted in a highly heterogeneous sample with wide variations in reported default rates, but this is refl ective of programmatic variability. We used a random-effects model, which is more appropriate for meta-analyses in which heterogeneity is anticipated, and attempted to explore potential sources of variation through subgroup analyses. However, this was limited by the quality of reporting. For example, one paper did not report any interventions to support patient retention, but on contacting the author seven incentives/enablers were provided; 26 thus, the fact that 31 papers did not report using any incentives/ e nablers does not necessarily mean that this was not done. However, the author survey response was poor, with less than half of the study authors contacted (33/75 authors) responding. Given the fact that all studies were observational in design, there are likely to be unmeasured factors that contributed to explaining the variability between studies. The differing definitions of default between studies also may mean that the proportion of patients defaulting was classifi ed differently, although the majority used the standard WHO defi nition, limiting this potential variation. Other key variables, such as DOT or type of nutritional intervention, were rarely explicitly defi ned. Only English language publications were included, resulting in the exclusion of 18 studies, which partly explains the lack of representation of studies from low-and middle-income settings (nine studies were from these regions); however, our review was broadly representative, capturing reports from 31 countries, less than a third of which were from high-income settings. Finally, the large number of subgroup analyses undertaken gives potential for spurious results. Nevertheless, the fact that this review was able to describe interventions from 78 studies including over 20 000 patients provides a solid starting point for future research.
While this review focused on interventions targeting patient reasons for treatment default, responsibility for ensuring treatment adherence must be shared by the health care system. 103 Treatment default may also result from disrespectful, uncaring treatment from the health care staff involved, 7 issues that are not systematically reported. An important area for future research would be to investigate the impact of interventions focusing on health care system improvement, for example the impact of intensive staff education on the default rates of patients in MDR-TB programmes. 104 
CONCLUSIONS
This review provides an overview of interventions used across a large number of studies and a wide range of settings, allowing a broad generalisability of these fi ndings to MDR-TB treatment programmes. The confi rmation of the benefi cial effect of DOT provision and the fi ndings of lower default through use of community health workers, standardised regimens and combinations of adherence interventions, provide evidence for the provision of patient-friendly DOT provision for MDR-TB management, particularly in the context of cost-effective decentralised care. These fi ndings may also support a move away from the controversial and ineffective use of legal action to enforce adherence. Perhaps one of the most important fi ndings of this review was our inability to identify any rigorous comparative studies to assess interventions to reduce default and improve retention in care. Only one prospective comparative cohort was identifi ed, comprising just 38 MDR-TB patients. This contrasts starkly with HIV/AIDS (acquired immune-defi ciency syndrome) care, for which over 90 randomised trials have been conducted to assess adherence support interventions. 105 Comparative prospective studies would greatly strengthen the evidence base to allow better decision making in practice and policy where resources are limited to achieve the goal of universal access to effective MDR-TB treatment. 
OBJECTIVE
To assess strategies to support adherence and reduce default in DR-TB treatment.
METHODS
Search strategy
MeSH and free word searches using terms for TB, treatment outcomes and drug resistance according to a compound search strategy ( 
Types of intervention
Any programmatic interventions enhancing treatment adherence rates and reducing default. Further information from studies reviewed in full will be obtained by sending an online standardised survey to the authors (Figure) .
Types of outcome • Proportion of patients defaulting from treatment
Data analysis
Point estimates and 95% confi dence intervals will be calculated for the proportion of treatment defaulters and pooled using a DerSimonian-Laird random effects model. Sub-group analyses will be carried out to determine the potential infl uence of clinical and programme interventions. Information on the following will be extracted as potential determining retention in care:
• 
